Suppression of Oral HHV8 Shedding With Valganciclovir
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in
suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that
valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in
the mouth.